By effectively targeting HER2-driven signalling while minimising off-target effects, Tucatinib represents a promising therapeutic option for HER2-positive breast cancer, including those with refractory disease or central nervous system involvement [29]. This evidence concerns the gene ERBB2 and breast carcinoma.